For IRAK4, the target detail page shows 11 inhibitors (http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2045%26familyId=579%26familyType=ENZYME#Inhibitors), six of which are selective, including the Pfizer compound (PF‐06650833; http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9667) which is a clinical lead for rheumatoid arthritis, demonstrating that IRAK4 is a druggable target in the pathway. The gene discussed is IRAK4; the disease is rheumatoid arthritis.